NEW YORK, Oct. 24, 2016 /PRNewswire/ -- The federal litigation recently established for dozens of Taxotere lawsuits alleging permanent hair loss is about to get underway in the U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order dated October 13, 2016, the Court will convene its Initial Case Management Conference on Thursday, November 10, 2016, at 10:00 a.m., CST. Among other things, the Order directs that the parties submit separate written statements to the Court by noon on Wednesday, November 2nd, indicating their preliminary understandings of the facts involved in the litigation and the critical factual and legal issues. Applications and nominations for appointment to the Plaintiffs' Steering Committee must be filed electronically in the master docket no later than 5:00 p.m. on October 24th. (In Re: Taxotere (Docetaxel) Products Liability Litigation - MDL No. 2740)
"Our Firm is investigating a number of Taxotere claims on behalf of individuals who allegedly experienced permanent alopecia following cancer treatment with this medication. We are pleased that this litigation will soon be underway, and will monitor its progress closely," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free legal evaluations to chemotherapy patients whose hair failed to grow back following treatment with Taxotere.
Taxotere Hair Loss Litigation
Initially approved to treat breast cancer, Taxotere (docetaxel) has since been cleared by the U.S. Food & Drug Administration (FDA) for use in patients with head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. Though Taxotere has been on the market for two decades, it was only in December 2015 that the U.S. label was updated to note that cases of permanent alopecia had been reported among chemotherapy patients who had treated with the medication.
Court records indicate that more than 80 Taxotere lawsuits have been filed in federal courts around the country on behalf of cancer patients who allegedly experienced permanent alopecia related to its use. While plaintiffs acknowledge that temporary hair loss is a common side effect of chemotherapy, they assert that Taxotere is more likely to result in permanent alopecia compared to equally effective alternative chemotherapy agents. They also point out that Sanofi-Aventis has long advised physicians, patients, and regulatory agencies in the European Union and Canada of Taxotere's potential to cause permanent and disfiguring hair loss, and question why the U.S. label merely stated that "hair generally grows back" following use of the drug.
Individuals who allegedly experienced permanent hair loss following chemotherapy with Taxotere may be eligible for compensation. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP